Table 2 Survivin inhibitors currently in phase I/II clinical trials
From: Impacting tumor cell-fate by targeting the inhibitor of apoptosis protein survivin
Mechanism of action | Compound | Clinical Trials | Indication |
|---|---|---|---|
Antisense oligonucleotides | LY2181308 | Phase I | AML |
| Â | Â | Phase II | AML, NSCLC (+docetaxel) and HRPC (+docetaxel) |
| Â | Terameprecol (EM-1421) | Phase I | Leukemia |
| Â | Â | Phase II | AML, NSCLC (+/- docetaxel), HRPC (+docetaxel) |
Transcriptional Repressors | Â | Phase I | Solid tumors |
| Â | YM155 | Phase II | NSCLC(+carboplatin/paclitaxel), HRPC (+docetaxel), HER2 negative breast cancer (+docetaxel) Melanoma |
| Â | Vaccine Therapy With Dendritic Cells - Transfected With hTERT-, Survivin- and Tumor Cell Derived mRNA + ex Vivo T Cell Expansion and Reinfusion | Phase I/II | Melanoma |
| Â | Multipeptide vaccine: PSMA and Survivin | Phase I/II | Prostate cancer |
| Â | Survivin peptide vaccine | Phase I/II | Solid tumors |
| Â | Multipeptide Vaccine: telomerase and survivin | Phase I | Breast cancer |
Immunotherapy | Multipeptide vaccine: MART-1, keyhole limpet hemocyanin, recombinant MAGE-3.1, survivin and autologous dendritic cells | Phase I/II | Melanoma |
| Â | Multipeptide vaccine: MART-1, gp100 and survivin antigens + GM-CSF +/- IL2 | Phase I | Melanoma |
| Â | Stem Cell Transplant, Chemotherapy, and Biological Therapy (CMV N495 peptide, CMV pp65 peptide, hTERT I540/R572Y/D988Y multipeptide vaccine, pneumococcal polyvalent vaccine, survivin Sur1M2 peptide vaccine) | Phase I/II | Multiple Myeloma |
| Â | Dendritic Cells Transfected With Survivin, hTERT and p53 mRNA | Phase I/II | Breast Cancer or Malignant Melanoma |
| Â | Survivin and telomerase peptide-pulsed dendritic cells | Phase I/II | Renal Cell Carcinoma |